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Mitochondria are arbiters in the fragile balance between cell life and death. These organelles present an
intricate membrane system, with a peculiar lipid composition and displaying transverse as well as lateral
asymmetry. Some lipids are synthesized insidemitochondria, while others have to be imported or acquired
in the form of precursors. Here, we review different processes, including external interventions (e.g., diet)
and a range of biological events (apoptosis, disease and aging),whichmay result in alterations ofmitochon-
drial membrane lipid content. Cardiolipin, the mitochondria lipid trademark, whose biosynthetic pathway
is highly regulated, will deserve special attention in this review. The modulation of mitochondrial mem-
brane lipid composition, especially by diet, as a therapeutic strategy for the treatment of some pathologies
will be also addressed.
 2013 Elsevier Ltd. All rights reserved.Contents1. Mitochondria: evolution, physiology and the role of their membrane lipids . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 514
2. Remodeling of mitochondrial membrane lipids in pathophysiology: an early event or a consequence?. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5142.1. Mitochondrial membrane lipids and apoptosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 515
2.1.1. Mitochondrial pathway for apoptosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 515
2.1.2. Mitochondrial membrane remodeling and signaling during apoptosis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5152.2. Remodeling mitochondrial membrane lipids to survive: the case of cancer cells. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 516
2.3. Cholesterol and cardiolipin alterations in human disease: beyond cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5182.3.1. The Barth Syndrome. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 518
2.3.2. Cardiac pathology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 519
2.3.3. Diabetes and other metabolic diseases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 519
2.3.4. Parkinson’s disease and oncogenic-associated cachexia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 520
2.3.5. Drug-induced mitochondrial toxicity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 520
2.3.6. Mitochondrial cholesterol alterations and disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 520
514 J.P. Monteiro et al. / Progress in Lipid Research 52 (2013) 513–5282.4. Mitochondrial membrane lipid composition changes in aging . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 520
3. Mitochondrial membrane lipids as a target for diet interventions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 522
4. Open perspectives and words of caution . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 523
Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 524
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5241. Mitochondria: evolution, physiology and the role of their
membrane lipids
Mitochondria aremembrane-enclosed cellular structures, which
are classically defined as energy-producing organelles, although
their influence extends to many other cell functions. In the classic,
although controversial at the time, endosymbiotic theory proposed
by Lynn Margulis in the late sixties [1], an amitochondriate anaero-
bic eukaryote engulfed an oxygen consuming proteobacterium. In
one of those chance events that most likely allowed for the expan-
sion of life on Earth, the engulfed bacterium was not destroyed,
but rather lived in symbiosis with its host. The emergent biological
system became equipped with skills to adapt to different types of
environment, especially oxygen-richniches. In fact, this newaerobic
organism, an ancestor of eukaryotic cells, earned the advantage of
using a wider variety of substrates to generate even higher amounts
of energy,which provided itwith a replicative superiority in relation
to competition [2]. By its turn, the proteobacterium gained a better
protection from the harshness of the environment and a steady flux
of substrates. Over millions of years, the proteobacterium evolved
into what we now recognize as the mitochondrion. Further evolu-
tion steps resulted in a remodeling ofmitochondria to suit the needs
of fungi, animals or plants. Thus, despite being mostly similar to
theirmammalian counterparts, plantmitochondria have interesting
differentiating features [3], including inner membrane alternative
oxidases (AOX) [4] and type II NAD(P)H dehydrogenases [5], which
result in high metabolic plasticity and make plants endowed with
a remarkable potential for adaptation. Interestingly, taking into ac-
count the widespread taxonomic distribution of AOX, which is also
present in prokaryotes and, among eukaryotes, in fungi, plants and
animals, it has beenproposed that the proteobacterial ancestor from
which mitochondria evolved were provided with AOX and this had
been lost over evolutionary time by vertebrates and arthropods [6].
Mitochondrial bioenergetics depends largely on the physiology
of the innermitochondrial membrane (IMM), which hosts the redox
complexes of the respiratory systemandphosphorylation apparatus
that performs the highly efficient energy-generating process known
as oxidative phosphorylation. In this process, the energymade avail-
able from the oxidation of nutrients is used to drive ATP synthesis.
Electrons from specific substrates, funneled to nicotinamide nucle-
otides (NAD+ or NADP+) or flavin nucleotides (FMN or FAD), enter
the mitochondrial electron transport chain, through which they
are transferred to oxygen [7]. As electrons flow through a sequence
of membrane-bound protein and non-protein carriers, protons are
pumped from the mitochondrial matrix to the intermembrane
space. Therefore, according to the chemiosmotic theory introduced
by Peter Mitchell [8], the free energy of substrate oxidation is con-
served as a transmembrane proton electrochemical potential (Dp),
part of which composed by the electric component (DW) which is
used to drive ATP synthesis by the ATP synthase complex, through
a rotational catalysismechanism [9]. Mitochondrial oxidative phos-
phorylation accounts for about 90% of cellular oxygen consumption
and provides more than 80% of the energy demands for cellular life
metabolism [10]. However, besides cellular energy production,
mitochondrial have other functions in the cell, including the modu-
lation of calcium signaling, regulation of cell death, themaintenance
of cellular redox balance and the housing of important biosynthetic
pathways [11]. Therefore, it is fair to say thatmitochondria functionas gatekeepers of cell life and cell death. In the latter case,mitochon-
dria have been associated with both apoptotic and necrotic cell
death [11], discussed in detail in the next section.
Mitochondrial membrane lipids are involved in a number of
processes as diverse as protein biogenesis, energy production,
membrane fusion and apoptosis [12]. Moreover, spatially defined
lipid distribution (Fig. 1A) may also affect mitochondrial processes
as fusion and fission or the topology of proteins in the membrane
plane [12]. In the particular case of energy production, evidence
that membrane lipids modulate mitochondrial respiration has
been generated by dietary manipulations of the lipid content in
mitochondrial membranes. These approaches have shown that die-
tary interventions that are able to influence mitochondrial mem-
brane lipid composition, hence modifying its physical properties
[13–20], alter respiration [20–29] as well as other mitochondrial
processes involving generation of reactive oxygen species (ROS)
[30] and Ca2+-induced MPT [20,31]. The role of membrane lipids
in mitochondria function is best exemplified by cardiolipin (CL),
the signature phospholipid of those organelles. CL has been linked
to a number of important mitochondrial processes, including oxi-
dative phosphorylation [32], apoptosis [33] and the assembly and
function of mitochondrial membrane proteins [34].
The phospholipid composition of mitochondrial membranes is
thought to be under genetic control, and varies markedly between
different tissues and organs within an individual animal, repre-
senting a specific feature of each membrane [35].
Under physiologic conditions, phospholipid composition of
mitochondria relies on the conjugated expression and activity of
a number of proteins involved in lipid synthesis and interconver-
sion. Mitochondrial regulation of phospholipid levels is not fully
understood, but it depends on the action of mitochondrial proteins,
as reported for CL and PE [36]. On the other hand, studies on genet-
ic manipulation of mitochondria membrane lipid content [37–39]
point to the need to maintain a ‘‘physiologic’’ lipid composition
of mitochondria membranes. We envision that environmental fac-
tors, including diet, can impact the genetic control of lipid synthe-
sis, remodeling and incorporation in membranes, thus inducing
alterations in membrane lipid composition. Despite diet-induced
changes in the expression/genetic regulation of mitochondrial pro-
teins have been reported [40,41], the mechanisms involved in the
regulation of mitochondrial lipid content and their susceptibility to
the interference of external stressors at the level of gene/protein
expression were not yet fully clarified. An alternative way for
external interventions to alter mitochondrial membrane lipid com-
position may be related with the supply of different lipid precur-
sors, which may be in excess or not available for lipid synthesis.
In the following sections, we will address issues regarding the
modulation of mitochondrial membrane lipid composition in the
context of apoptosis, cancer or other diseases and aging (Section 2),
as well as the possibility to explore diet-induced alterations in
mitochondrial membrane lipids as a strategy for therapeutic pur-
poses (Section 3).2. Remodeling of mitochondrial membrane lipids in
pathophysiology: an early event or a consequence?
A great deal of data has been accumulated regarding alterations
of cell and organellar lipids in health and disease conditions. An
Fig. 1. Panel A (left) shows the general structure of mitochondria and most relevant differences in terms of membrane lipid composition between the inner mitochondrial
membrane (IMM), the outer mitochondrial membrane (OMM) and mitochondrial contact sites (MCS’s). The IMM displays invaginations (cristae) and defines the
mitochondrial matrix. The inter-membrane space is delimited by IMM and OMM. The general lipid composition (in percentage of the total lipid) of the IMM, the OMM and
MCS’s reports to mouse liver mitochondria, according to Ardail et al. [256]. Panel B (right) shows some of the membrane lipid alterations described to occur during apoptosis,
namely GD3 translocation from plasma membrane lipid rafts to mitochondria, an increase in ceramide, a decrease in CL content, and impairment of its acyl chain remodeling
(indicated in the figure by a prohibition sign), resulting in MLCL accumulation. CL peroxidation, followed by cyt c (‘‘c’’) release through pro-apoptotic pores in the OMM, loss of
CL asymmetric distribution between the IMM and OMM, increase in DAG, phosphorylated PI and lysophospholipids (including, as described, MLCL), as well as a decrease in
linoleyl PC were also reported as taking place during apoptosis. CLim: immature CL; MLCL: monolyso CL; CLper: peroxidized CL.
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sue to be solved by functional lipidomics, which focuses on unravel-
ing the molecular mechanisms that trigger (upstream events) and
are triggered by (downstream events) membrane lipid alterations.
Therefore, the major challenge for lipidomic research is to find out
howmembrane lipid changes are associated to known or unknown
cell signaling pathways. In this section, alterations of mitochondria
membrane lipids related to apoptosis, cancer or other diseases and
aging are reviewed, and a mechanistic perspective is provided
whenever sufficient data are available to support it.2.1. Mitochondrial membrane lipids and apoptosis
2.1.1. Mitochondrial pathway for apoptosis
As discussed briefly above, mitochondria have an important role
in the modulation of cell death. The ‘‘intrinsic’’ or mitochondrial
pathway to cell death becomes activated in response to a variety
of apoptogenic stimuli, such as growth factor deprivation, hypoxia,
cell detachment, oxidative stress andDNAdamage [42,43]. This pro-
cess results in increasedmitochondrialmembrane permeability and
ultimately in the release of pro-apoptotic factors such as cyto-
chrome c (cyt c), Smac/DIABLO, Omi/Htr2A, and AIF (apoptosis-
inducing factor) from mitochondria, leading to the activation of a
highly complex and regulated cell death program. Several mecha-
nisms have been proposed to occur during the permeabilization of
OMM,aswill bedescribed in the following section.Anotherpathway
leading to apoptosis involves mitochondrial calcium overload,
which triggers the opening of the mitochondrial permeability tran-sition pore (PTP) through a phenomenon termedmitochondrial per-
meability transition (MPT). In vitro, the MPT causes disruption of
oxidative phosphorylation andmitochondrial swelling due to influx
of water, leading to the rupture of the mitochondrial outer mem-
brane (OMM) and subsequent release of pro-apoptotic factors [44].
Indeed, more than an in vitro-only effect, theMPT is a common phe-
nomenon in tissue injury [45].
When cellular ATP levels become abnormally low, which may
result from mitochondrial dysfunction, classical apoptotic triggers
typically cause necrotic demise, showing that sustained ATP pro-
duction is required for the cells to engage the apoptotic program
[46]. Necrosis results in the swelling of the cell and the disruption
of the plasma membrane, with consequent release of cellular con-
tent to the extracellular space. As opposed to apoptosis, uncon-
trolled necrosis triggers an inflammatory response that can cause
further damage to surrounding cells [47].2.1.2. Mitochondrial membrane remodeling and signaling during
apoptosis
Several alterations in mitochondrial lipid content and distribu-
tion during apoptosis have been reported (Fig. 1B). An increase in
diacylglycerol (DAG), monolysocardiolipin (MLCL) and phosphory-
lated phosphatidylinositol (PI) was described in mouse liver mito-
chondria. On the other hand, CL and linoleic acid-containing
phosphatidylcholine (PC) contents were reported to be decreased,
with the same trend observed in mitochondria from other origins
[48]. These lipid changes appear to reflect a deficiency in the
biosynthesis of PC, impacting downstream the remodeling of CL,
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crease in MLCL is often concomitantly found with the initial loss
of CL [49]. The content in other lysolipids (C16:0 and C18:1 lysoPC)
also increases during the early stages of the apoptotic process [50]
and may play a crucial, although not fully clarified, role in assisting
the pro-apoptotic proteins Bax and Bak in the process of OMM per-
meabilization [48].
During apoptosis, OMMCL content has been reported to increase
from very low to up to 40 mol% of its total content [51]. On the other
hand, CL distribution between the two leaflets of the IMM [52] was
shown to change from60:40 mol% between the inner leaflet (matrix
side) and the outer leaflet (intermembrane space side) to about
30:70 mol%, during the early phase of apoptosis, with CL transloca-
tion to the outer leaflet of the IMM resulting in increased association
with cyt c. Moreover, CL peroxidation was suggested to have a key
role in mitochondrial apoptotic signaling. Thus, upon an apoptotic
stimulus, a tight complex between cyt c and CL is formed and cyt c
is converted froma loosely attachedelectron carrier protein to a per-
oxidizing molecule [53,54]. Then, a catalytic peroxidase activity
selectively targeted towards CL is initiated. This oxidation process
leads to a decrease of cyt c affinity for CL and apparently mediates
the release of pro-apoptotic factors frommitochondria into the cyto-
sol, including cyt c itself, by mechanisms not yet fully understood.
[51]. Interestingly, CL as well as phosphatidylethanolamine (PE),
predominates in IMM-OMM contact sites. These phospholipids are
both non-bilayer lipids, adopting an inverted hexagonal phase (HII)
in the absence ofmembrane constraints. Although somehow specu-
lative, it has been proposed that non-bilayer lipids could be involved
in membrane fusion at the contact sites, fostering CL access to the
cytosolic face of OMM [55], where it would directly interact with
tBid, offering a docking site for this active form of the pro-apoptotic
protein Bid. This would be the first step for triggering the action of
Bax and Bak (other pro-apoptotic Bcl-2 proteins), thus leading to
OMM permeabilization. A more recent view of the involvement of
CL-enriched contact sites in apoptosis-associated events was pre-
sentedby Sorice et al. [56]. In thiswork, a hypotheticmodelwas pre-
sented proposing that contact sites act as activating platforms (raft-
likemicrodomains) atwhich caspase-8 is anchored, cleaving its sub-
strate (Bid). The resulting product, tBid, is then recruited to promote
Bak/Bax oligomerization. The segregation of these domains from the
rest of the OMMwould create membrane defects, fostering apopto-
genic factor leakage.
Sphingolipids also play a crucial role in the early stages of apop-
tosis. Mitochondria are provided with enzymes that catalyze the
synthesis and the hydrolysis of ceramide, a lipid that occupies a
central position in sphingolipid metabolism [57]. Thus, ceramide
can be generated in the endoplasmic reticulum as well as in mito-
chondria [58] by de novo synthesis, which can involve the acylation
of sphinganine to form dihydroceramide in a reaction catalyzed by
ceramide synthase, or the reverse reaction of ceramide hydrolysis
catalyzed by ceramidase, using as substrates sphingosine and fatty
acids.
It is well known that ceramide levels in mitochondria undergo a
significant increase prior to the onset of apoptosis. On the other
hand, ceramide-induced adverse effects onmitochondria have been
extensively reported, namely increased generation of ROS, alter-
ation of calcium homeostasis, collapse of the inner mitochondrial
DW and release of proteins from the intermembrane space [59].
However, the mechanisms underlying ceramide-induced apoptosis
at the mitochondrial level are not yet fully clarified. According to
someauthors [59–61], this event involves adirect actionof ceramide
on mitochondria, although the immediate consequences of this
interaction and the role on apoptotic alterations are still under de-
bate. Siskind et al. demonstrated that ceramide forms protein-per-
meable channels in isolated mitochondria, thus raising the
permeability of the OMM not only to cyt c, but also to all smallproteins (up to 60 kDa in size) at physiologically relevant ceramide
concentrations [60]. Interestingly, these channels, formed by trans-
membrane columns of ceramide molecules held together by inter-
molecular hydrogen bonds [59], were not formed within the
plasmamembrane of erythrocytes [60], revealing a certain specific-
ity for the lipid environment of the OMM. Other authors alterna-
tively proposed that the direct interaction of ceramide with the
OMM results in its permeabilization due to the formation of cera-
mide-rich macrodomains which recruit Bax molecules, regulating
their insertion and subsequent oligomerization to form pores [61].
Therefore, ceramide was proposed as amembrane-based stress cal-
ibrator, acting through a reorganization of the OMM structure. This
effect is compatible with ceramide propensity to promote lateral
phase separation in a fluid phospholipid membrane inducing the
formation of extremely ordered and rigid ceramide-enriched plat-
forms [62]. This has been proposed to serve clustering of receptor
molecules, reorganization of signaling molecules and to constitute,
at the plasmamembrane level, sites to promote and amplify signal-
ing processes [63]. As an alternative to a direct interaction of cera-
mide with mitochondria, the activation of the pro-apoptotic
proteins BAX/BAKmediated by the sphingolipid metabolites sphin-
gosine-1phosphate (Sph1P) and hexadecenal was proposed as the
mechanism underlying OMM permeabilization [64]. According to
this proposal, ceramide, constitutively generated from sphingomy-
elin by a neutral sphingomyelinase in a mitochondrial-associated
compartment, is transferred to mitochondria and produces Sph1P
andhexadecenal,whichdirectly regulateBAKandBAX, respectively,
by stabilizing the active conformation of these effector proteins.
Hexadecenal, a product of Sph1P degradation, would promote BAX
monomer conformational alterations that favored oligomerization,
leading hence to permeabilization of OMM and apoptosis.
GD3, a ceramide-based glycolipid, has been reported to accu-
mulate during apoptosis in mitochondria, where it is supposed to
trigger specific events involved in the apoptogenic program by
interacting with mitochondrial raft-like microdomains [65]. In fact,
GD3-enriched raft-like domains are formed during Fas/CD95-med-
iated apoptotic signals, consisting of well-ordered structures con-
nected to the internal mitochondrial cristae in mitochondria [66].
After a pro-apoptotic stimulus, a number of mitochondrial pro-
teins, such as ATP synthase, VDAC-1, VDAC-2 [67] and hFis [68],
converge to those raft-like mitochondrial microdomains, which
contribute to apoptosis-associated modifications and late apopto-
genic events, as previously mentioned [69]. GD3 was considered
as an actual structural component involved in the formation of
the PTP, and contributing to the formation of a multimolecular
complex that includes VDAC-1, Bcl-2 family and fission proteins,
such as hFis [68]. Following CD95/Fas crosslinking, Bax, Bak, cas-
pase-8 and tBid are also recruited to these CL- and GD3-enriched
mitochondrial raft-like microdomains, as mentioned above
[66,56]. Therefore, GD3 has been proposed as playing a crucial role
in the context of MPT induction and cyt c release and subsequent
cell death promotion [66].
2.2. Remodeling mitochondrial membrane lipids to survive: the case of
cancer cells
The classical metabolic phenotype of cancer cells consists of an
increase in glycolytic fluxes under aerobic conditions, which was
first described by Otto Warburg almost a century ago [70]. The
Warburg effect involves a much more complex metabolic picture,
involving the orchestration of multiple factors [71], and is reflected
in pronounced alterations in bioenergetic and apoptotic-related
cellular signaling. These can account for oncosuppression, onco-
genesis, tumor progression and chemotherapy resistance shown
by cancer cells, which are remarkably more resistant to death
induction than their normal analogs [72]. Several specific
Fig. 2. Some features of mitochondrial membrane lipid composition (left) and mitochondria bioenergetics (right), which are altered in cancer cells as compared to normal
cells. Bioenergetic remodeling is known to occur in the majority of cancers, involving multiple partners, including transcription factors and metabolites, often resulting in
increased glycolytic fluxes with decreased oxidative phosphorylation. Increased mitochondrial electric transmembrane potential is a trademark characteristic of many
tumors, which is susceptible to be targeted by positively-charged molecules. Mitochondrial membrane lipid alterations, including changes in cardiolipin remodeling and in
cholesterol content, can contribute to modify the activity of that organelle, including through inhibition of the respiratory chain. At the same time, membrane lipid
alterations, especially concerning the fatty acyl chains that compose cardiolipin, can increase the resistance to chemotherapeutics through altering the peroxidation index of
that phospholipid (MUFA/PUFA ratio).
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served in cancer cells, with the activities of certain enzymes in-
volved in oxidative phosphorylation being decreased in
mitochondria from these cells. Increased gluconeogenesis and glu-
taminolysis, a decrease in pyruvate oxidation, increased lactate
production accompanied by decreased fatty acid beta-oxidation
have been reported in mitochondria from different types of tumors
[73].
In the whole metabolic remodeling framework in cancer, the
mitochondrial membrane composition was described to undergo
alterations (Fig. 2). Analysis of the inner membrane lipid composi-
tion of various tumor mitochondria indicated an higher cholesterol
content [74–76], along with changes in the relative amount of indi-
vidual phospholipids [77]. Alterations in lipid acyl components
have also been observed, the phospholipids of mitochondria from
tumour cells showing generally shorter and less unsaturated acyl
chains than those from normal cells [78,79].
Lipid composition alterations in mitochondrial membranes are
expected to impact the mitochondrial phenotype, which may con-
tribute to the Warburg effect and to the decreased susceptibility to
apoptotic stimuli. Altered mitochondrial membrane composition
and dynamics in cancer cells may decrease the activity of the respi-
ratory chain, a relationship that has already been described for CL
[77]. On the other hand, a remodeling in mitochondrial membrane
lipid composition may also contribute to the increased mitochon-
drial DW observed in many tumors [80,81]. Increased mitochon-
drial DW may have as a consequence an increased generation of
ROS by the respiratory chain, which may be important in the con-
text of cancer development, including by regulating Kras-mediated
tumorigenicity [82], and stabilizing the hypoxia-inducible factor-
1a [83]. The mechanisms underlying these phenomena appear to
involve both protein and membrane lipid alterations. One possibil-
ity is that altered ATP synthase protein content/activity can de-
crease proton conductance through the Fo subunit, increase
mitochondrial DW and decrease ATP generation thus contributing
to the Warburg effect [84]. Uncoupling proteins (UCP) would also
be an attractive candidate to explain those alterations, since a
decreased expression of this class of proteins in tumors would in
theory contribute to increase mitochondrial DW. Nevertheless,the still incomplete knowledge of the functional meaning of the
different UCP isoforms justifies that the results obtained so far
regarding the function of this class of proteins in different tumors
is still under discussion [85,86]. In fact, an increase in UCP2 was
identified in breast and in many other tumors, including leukemia,
ovarian, bladder, esophagus and lung [87]. Ectopic expression of
UCP2, surprisingly, was able to increase the tumorigenic properties
of a breast cancer cell line. The authors proposed that increased
expression of UCP2 results from an adaptive response to the hyper-
polarization of mitochondrial membranes [87], showing that mod-
ulation of UCP2 content is a consequence and not a cause of
hyperpolarized DW. In terms of membrane lipids, the cholesterol
content has been shown to increase in the inner mitochondrial
membrane of Ehrlich tumor mitochondria, an effect that was sug-
gested to increase membrane order and decrease proton passive
permeability through that membrane, thus increasing DW [74].
Other outcomes of mitochondrial membrane cholesterol enrich-
ment include reduced activity of the respiratory chain [88], pro-
moting a phenotype characteristic of the Warburg effect, and
increased resistance to chemotherapy [75]. The role of cholesterol
in chemotherapy resistance has been related to its capacity to in-
crease membrane lipid packing, thus decreasing mitochondrial
membrane permeabilization and impairing Bax-driven release of
cytochrome c to the cytosol [75]. Some studies have suggested that
the increase in cholesterol in mitochondrial membranes may be di-
rectly related with caveolin-1 deficiency [89], which has been de-
scribed to underlie carcinogenesis in different models including
colorectal and breast cancer [90,91]. Interestingly, loss of tumor
stromal caveolin-1 leads to increased oxidative stress and induced
the so-called ‘‘reverse Warburg effect’’, in which tumor-associated
fibroblasts with deficient mitochondrial function and increased
oxidative stress and autophagic fluxes feed tumor cells with sub-
strates for the respiratory chain [91,92]. Other studies have sug-
gested that the outer membrane protein voltage-dependent
anion channel (VDAC) is involved in cholesterol distribution in
mitochondrial membranes in tumors [88].
CL has also attracted a lot of interest in a cancer context. A
shotgun lipidomics study aiming at determining CL content and
composition in mitochondria from subcutaneously grown brain
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tumor, and two microgliomas, showed evident alterations in CL
content and composition in all tumors [77]. These abnormalities
included an abundance of immature molecular species along with
alteration of mature molecular species, probably related to defects
in CL synthesis and remodeling. Data regarding this mitochondrial
phospholipid in terms of cancer are very diverse, ranging from the
appearance of immature molecular species and decreased CL con-
tent in brain tumors [77], decreased CL content in rhabdomyosar-
come cells [93], increased CL content and fatty acid remodeling in a
rat model of peritoneal carcinosis [94] to unaltered total CL
amount in a mouse strain with high propensity to form spontane-
ous gliomas [95]. This last study involved two strains of mice, one
of which (VM/Dk) with a much higher propensity to develop glio-
mas than the other, taken as the control strain (C57BL/6J). The VM/
Dk strain not only contained higher amounts of ethanolamine glyc-
erophospholipids, phosphatidylserine (PS) and ceramide, but also
displayed a lower number of CL species than the control strain
[95]. Interestingly, although the activity of complexes I-III was de-
creased in the VM/Dk strain, complex IV activity was higher [95].
This disparity of impact on respiratory chain activity may have re-
sulted from the differences in CL species, which should have influ-
enced the rate of ROS production and ATP generation, although
sadly these parameters of mitochondrial function have not been
measured in this work.
Regarding the drug resistance phenotype, studies on MCF-7 hu-
man breast cancer cells showed an increase of CL content (ex-
pressed in percentage of cell total phospholipids) in doxorubicin-
resistant and cisplatin-resistant cancer cells, as compared to
drug-sensitive parental cells [96]. However, other lipid alterations
were observed in those drug resistant cells, namely an increase in
cholesterol and sphingomielyn content, which the authors suggest
to be involved in lipid raft dynamics, thus affecting protein–protein
and protein–lipid interactions. The characterization of CL species in
drug-sensitive vs. drug-resistant cells was not performed in this
study. Evidence has been obtained that CL remodeling is important
in determining CL peroxidation catalyzed by cyt c and consequent
cyt c dissociation from the inner mitochondrial membrane [53,54].
Therefore, the decreased resistance to apoptosis in tumor cells may
be predictably related with less oxidizable CL species. In terms of
CL content and its relationship with cell resistance to apoptosis, a
very comprehensive study has been carried out by Huang et al.
[37] showing that CL deficiency counteracts rather than promotes,
as stated by other authors [97], cytochrome c release and apoptosis
induced by several stimuli. Huang and collaborators remarked that
discrepant results obtained by Choi et al. might be due to the
methodology used for CL quantification: a radioactive method
based on the integration of [3H] palmitic acid into phospholipids
instead of evaluating the content of CL with respect to the total
phospholipid phosphorus, as performed by Huang et al. These
authors argued that, since palmitate has shown to be a poor sub-
strate for CL synthase [98], a predictable low incorporation of the
radiolabel in CL should have occurred, thus disabling an accurate
determination of CL content changes relative to other lipids.
Facing these different results, it is not easy to establish a model
for the effects of CL on cancer etiology. As a general consequence,
we may anticipate that alterations in CL:protein ratio or in CL spe-
cies may alter the activity of different respiratory chain proteins,
thus inhibiting electron flux and the efficiency of oxidative phos-
phorylation [94], contributing to the Warburg phenotype. But the
story is certainly far more complex. The balance between pro-
apoptotic and anti-apoptotic proteins present in the OMM, critical
in the context of apoptosis, is altered in a variety of tumors. In fact,
the mitochondrial apoptotic pathway is compromised by a read-
justment between anti-apoptotic and proapoptotic promoters, in
favor of the former [99].Targeting mitochondrial alterations has become a promising
strategy for the induction of apoptosis in tumor cells. The aforemen-
tioned proliferative and bioenergetic differences between normal
and tumor cells provide an opportunity to selectively target cancer
cellmitochondria or evenuse themasbiomarkers for early detection
of cancer [71,73]. As an example, the abovementioneddifferences in
DW have been used as part of a therapeutic strategy, in which delo-
calized lipophilic cations are selectively accumulated in tumor cells.
Someof these compounds have in fact exhibited efficiency in the de-
miseof cancer cells either in vitroor in vivo [100–108].However, effi-
cient mitochondrially-targeted therapies must be based on the
coordinated targetingof asmuchcancer features as possible, namely
cellular energy metabolism, mitochondrial stability and mecha-
nisms responsible for apoptosis resistance [109].
In summary, this section highlighted a particular case of mito-
chondrial membrane remodeling towards cell survival and fast
proliferation, with different examples pointing to lipid membrane
and protein alterations in tumors, which can contribute to the
Warburg phenotype and to escape from basal or chemotherapy-in-
duced cell death. Cardiolipin appears to be particularly involved in
this process, a phenomenon that is observed in the context of other
human pathologies (see the following section).
2.3. Cholesterol and cardiolipin alterations in human disease: beyond
cancer
Several pathologic conditions have been proposed to promote
changes in mitochondrial lipid composition, which may be impli-
cated in alterations of mitochondrial function and in disease pro-
gression. Two lipids will be specially focused in this section: CL
and cholesterol. Alterations associated with CL content and fatty
acid composition have shown to play an important role in a disease
context. Reduced CL levels (the most frequently reported patholog-
ical alteration regarding this lipid) [110], CL oxidation and/or alter-
ation of its molecular composition have been associated with
mitochondrial dysfunction in multiple tissues and in several phys-
iopathological conditions, including ischemia/reperfusion, differ-
ent thyroid states, diabetes, heart failure and Barth syndrome
[111–115]. An important note of caution is that in most cases there
is no definitive evidence whether the alteration in CL amount/spe-
cies is located upstream or downstream of the disease process and
the impact of that specific defect on the overall mitochondrial
phenotype.
2.3.1. The Barth Syndrome
Barth Syndrome (BTHS) is a paradigmatic example of a disease
in which a clear association between the pathological phenotype
and a defect on a mitochondrial lipid has been established. BTHS
is an X-linked disease [116], often fatal in childhood and resulting
in congestive heart failure in infants [117]. This multisystem inher-
ited disorder is characterized by cardiomyopathy, skeletal myopa-
thy, growth retardation, neutropenia and organic aciduria [118–
120]. A broad spectrum of clinical manifestations, with different
levels of severity, has been observed in BTHS patients, which com-
plicates the diagnosis of the disorder, due to the difficulty in differ-
entiating it from other cardiomyopathy syndromes in infants,
based solely on clinical findings.
Studies of familial cardiomyopathies have shown that this dis-
ease is linked to the TAZ or G4.5 gene (previously termed tafazzin),
located at Xq28 [116], which is highly expressed in the cardiac and
skeletal muscle. The primary transcript of this gene can produce
different mRNAs by alternative splicing, producing proteins that
differ at the N-terminus and at the central region [116]. The detec-
tion of a significant sequence homology between the TAZ gene and
genes coding for phospholipid acyltransferases led to the hypothe-
sis that impairment of lipid metabolism should be involved in
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a specific respiratory complex, were detected in mitochondria from
different cells of BTHS patients [122,123], strengthening the
hypothesis that the cause of this disease resided on membrane li-
pid composition alterations with consequent perturbation of lipid–
protein interactions. The impairment of mitochondria function, in
turn, could explain the occurrence of characteristic clinical mani-
festations of BTHS, such as cardiomyopathy and muscle weakness.
Since CL plays a crucial role in mitochondria complex assembling,
stability and function [124,32], it would not be surprising that TAZ
mutations impacted on CL homeostasis. In fact, a decrease of CL
content [117] and alterations in CL remodeling/maturation, re-
flected in impaired incorporation of linoleic acid into CL [125]
and a specific decrease of tetralinoleoyl-CL [117,126], were re-
ported in a variety of tissues from BHTS patients. An extensive
study involving children with genetically proven BHTS and chil-
dren exhibiting BTHS-like disorders (lacking TAZ mutations)
showed that CL analysis in platelets can provide a valuable diag-
nostic tool to identify cardiomyopathies caused by TAZ mutations,
since only in this case CL abnormalities were detected [117]. How-
ever, besides CL, other phospholipids, namely phospatidylcholine
and phosphatidylethanolamine (PE), exhibited a non-characteristic
fatty acid composition, resulting in a deficiency of palmitoyl-arach-
idonoyl-glycerol species in several tissues, with potential impact
on eicosanoid-dependent signal pathways [117].
The synthesis of characteristic CL species in mitochondria in-
volves two steps: (a) transfer of an activated phosphatidyl group
from phosphatidyl-cytidine monophosphate to phosphatidylglyc-
erol (PG), catalyzed by cardiolin synthase and (b) CL molecule
remodeling by tafazzin-catalyzed transacylation, in order to pro-
duce cell and tissue-specific CL species, namely tetralinoleoyl-CL,
a dominant molecular species in animal and plant tissues [127].
Therefore, it is conceivable that alterations of the characteristic
CL acyl-composition detected in BTHS result from impaired tafaz-
zin activity. On the other hand, accumulation of MLCL molecules
has been associated with BTHS [128]. Malhotra et al. [129] stated
that this effect was due to the action of a mitochondrial calcium-
independent phospholipase A2 (iPLA2-VIA), which promoted CL
deacylation. Using a tafazzin-deficient Drosophila model of BTHS,
which exhibited poor motor function in parallel with abnormal
mitochondria, low CL content and CL species with abnormal fatty
acid composition, the authors demonstrated that the inactivation
of mitochondrial calcium-independent iPLA2-VIA could be a strat-
egy to revert manifestations associated with tafazzin deficiency
[129]. Also, the chemical inhibition of calcium-independent phos-
pholipase A2 from Barth patient lymphoblasts restored the MLCL/
CL ratios to the values detected in normal cells. Since an important
consequence of TAZ mutations that contribute to BTHS is related to
MLCL accumulation, the inhibition of the deacylation step should
be envisaged as a partial solution of the problem. On the other
hand, this therapeutic intervention should spare healthy cells
and target specifically the tissues affected by the disorder.
Another interesting issue concerns the specificity of CL acyl pat-
terns, resulting a priori from fostering specific transacylations in
normal mitochondria. Recent studies showed that tafazzin itself
does not display a high specificity for their lipid substrates, react-
ing with a great variety of phospholipids and lysophospholipid
species [130–132], although its activity is greatly influenced by
the physical properties of the matrix in which lipid substrates re-
side [130], being lower for lipids highly packed in bilayer phases.
Moreover, Schlame et al. [130] showed that the characteristic CL
species of normal mitochondria (tetralinoleoyl-CL) could be
formed in vitro in the presence of purified tafazzin, under condi-
tions that favor inverted hexagonal lipid arrangements. It was thus
proposed that tafazzin acts in specific membrane lipid domains,
explaining why its activity does not equilibrate the fatty acidcomposition of all mitochondrial phospholipids [130,133]. On the
other hand, tafazzin-induced formation of tetralinoleoyl-CL (a
non-bilayer lipid) in highly curved lipid domains is expected to
have a great impact on fostering mitochondria fission and fusion
phenomena, which require transient destabilization of lipid bi-
layer, or on favoring lipid arrangements in membrane regions with
very high curvature, such as those in contact sites between the in-
ner and outer mitochondrial membranes. Notably, these regions
are enriched in CL and seem to play a crucial role in clustering
and organization of apoptotic signals on mitochondria [56], as pre-
viously reported in this work.
2.3.2. Cardiac pathology
A loss of heart mitochondria CL following ischemia has been de-
scribed in the early 1980s [134,135], and has since been well doc-
umented in a variety of tissues. CL depletion accompanied by loss
of cytochrome c during the ischemia phase was shown to lead to
increased generation of hydrogen peroxide by the respiratory
chain [136]. On the other hand, chronic cardiac overload leading
to experimental heart failure, results in loss of tetralinoleoyl-CL
with consequent decrease in the activity of cytochrome c oxidase
[115]. A similar effect was observed in rats suffering from rapid
pressure-overload hypertrophy and failure by chronic aortic band-
ing. In this case, a reduction in the linoleoyl content in cardiac
mitochondria CL was reported [137,138]. A reduction of heart CL
content was also reported during the progression of heart failure
in cardiomyopathic hamsters. The authors of this report ascribed
this event to a reduction of the diacylglycerol content in heart
and impaired phospholipid biosynthesis [139]. CL loss during car-
diac pathologies may result from deficient biosynthesis/remodel-
ing or increased degradation (including oxidation) and certainly
affect mitochondrial energy generation [140].
2.3.3. Diabetes and other metabolic diseases
Recent reports indicate a reduction of mitochondrial CL levels
and alterations of CL acyl chain remodeling, resulting in increased
incorporation of the highly unsaturated docosahexaenoic acid, in
the hearts of streptozotocin (STZ)-treated diabetic mice [141].
Whether these specific CL alterations, occurring in an early stage
of diabetes, influence the development or progression of diabetic
cardiomyopathy remains unknown. A recent study demonstrated
that transgenic expression of CL synthase decreases the incidence
of CL remodeling processes that ultimately cause degeneration of
mitochondrial function during STZ-induced diabetes [142]. Not
only mitochondrial dysfunction was mitigated by cardiolipin syn-
thase expression in the diabetic myocardium, but also a marked in-
crease in protective eicosanoids was observed [142]. Although this
interesting study allows foreseeing a therapeutic role for this en-
zyme within the scope of diabetes-induced alterations of mito-
chondria bioenergetics and signaling, the truth is that we are far
from understanding the mechanisms underlying the benefic effects
resulting from the manipulation of cardiolipin synthase.
In another context, an increase inCL synthase activity andCL con-
tent in rat heart [143–145] and liver mitochondria [146] was found
inhyperthyroidic rats,which resulted in an increase in the activity of
multiple CL-dependent mitochondrial proteins and processes. Con-
versely, drug-induced hypothyroidism resulted in a marked loss of
CL content andCL synthaseactivity inheartmitochondria [147]. This
study also showed that rat heart monolysocardiolipin acyltransfer-
ase activity is regulated in parallel and in a concerted manner with
the biosynthesis and content of cardiac CL.
A significant decrease in CL mitochondrial content and a rele-
vant increase in the level of peroxidized CL were reported in
non-alcoholic fatty liver disease. These changes in CL content were
related to the decrease in complex I activity found in liver mito-
chondria from rats to which this disease was diet-induced, since
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control livers by exogenously added CL. Moreover, the effect of
exogenous CL was not reproduced by other phospholipids nor by
peroxidized CL [148].
2.3.4. Parkinson’s disease and oncogenic-associated cachexia
Intriguing evidence for a potential role of CL alterations in Par-
kinson’s disease has been provided [149]. Mice lacking a-synuclein
exhibited a 22% reduction in CL mass in the brain, a 25% reduction
in the CL content in n-6 polyunsaturated fatty acids (including
C18:2), and a 51% increase in the CL content in saturated fatty
acids. A 23% reduction in PG (a CL precursor) was also detected,
without any changes in the content of other brain phospholipids
or mitochondrial density, suggesting that the CL biosynthesis path-
way should have been selectively impaired.
Cachexia is a serious consequence of a carcinogenic process.
Inflammation and disruption of metabolic and energy balance re-
sult in a decrease of body mass, mostly originating from a deple-
tion of muscle tissue [150]. Using animal models of peritoneal
carcinosis, a decreased efficiency of liver mitochondrial function
was observed, concomitantly with an increase in energy wasting
and with a lower n-6/n-3 PUFA ratio in the carcinosis group, as
compared to the control group [94]. Interestingly, very large
(12-fold) increase in ROS generation by hepatic mitochondria
was observed in the same group [94]. Although this alteration
was not investigated in other tissues (namely skeletal muscle),
this investigation makes way for therapies aimed at improving
mitochondrial efficiency to prevent cachexia derived from differ-
ent pathologies, including cancer. Moreover, a recent review [151]
provided clues suggesting that alterations in CL composition may
be behind a decrease in mitochondrial efficiency in cancer
cachexia.
2.3.5. Drug-induced mitochondrial toxicity
Cardiolipin has also been involved in the mechanisms of toxic-
ity of several drugs. One particular example is Doxorubicin (DOX),
an anti-cancer agent whose clinical usage is associated with a
cumulative and dose-dependent cardiotoxicity, in which mito-
chondria appear to play an important role [152–154]. DOX inhibits
the activity of several mitochondrial proteins in the heart [155–
157], which result from a specific drug interaction with CL, exclud-
ing this phospholipid from the lipid matrix surrounding the protein
complexes indirectly affected by DOX [158–160]. Recent data dem-
onstrated that tacrine, an acetylcholinesterase inhibitor used in the
treatment of Alzheimer’s disease, promotes a significant distur-
bance in the mitochondrial phospholipid content in the brain of
treated rats, including a decrease in CL and an increase in oxidized
aminophospholipids [161].
On the other hand, a great diversity of mitochondrial-active
molecules, such as the anti-inflammatory nimesulide [162], the
protonophore carbonylcyanide p-trifluoromethoxyphenylhydraz-
one (FCCP) [163] and the precursor of vitamin K menadione (2-
methyl-1,4-naphthoquinone or vitamin K3) [164] disturb lipid or-
der and organization in mitochondrial membrane-mimicking mod-
els, which may contribute to the adverse mitochondrial effects
exerted by those compounds. Non-lamellar CL-containing struc-
tures induced by FCCP and menadione were suggested to have a
key role in the insertion of those molecules in IMM lipid milieu
and influence lipid and protein topology, namely in CL-enriched re-
gions such as the contact-sites, with predictable impact on mito-
chondrial functioning.
2.3.6. Mitochondrial cholesterol alterations and disease
Accumulation of cholesterol in mitochondria seems to be a key
step in the progression of some pathologic conditions, including
steatohepatitis, carcinogenesis and Alzheimer disease [165].Interestingly, Alzheimer disease has been considered as a disorder
of mitochondria-endoplasmic reticulum (ER) crosstalk, which oc-
curs through mitochondria-associated ER membrane (MAM)
[166]. This ER sub-domain, which is physically connected to the
OMM, constitutes a crossroad between signal transduction and
metabolic pathways, with impact on mitochondria function and,
hence, on cell fate [167]. In recent years, this membrane compart-
ment has deserved special attention in a lipidomic perspective,
since it has been recognized as an intracellular lipid raft-like struc-
ture, enriched in cholesterol and sphingolipids organized in a li-
quid-ordered phase, thus promoting an increased thickness of
the bilayer as compared to the surrounding ER membrane [166].
Such structural characteristics make MAM able to recruit certain
proteins, excluding others. Among others, proteins whose trans-
membrane domains favor a ‘‘hydrophobic matching’’ with MAM
bilayer will be preferentially selected to reside in that region.
According to the ‘‘MAM hypothesis’’ for AD [166], the key catalytic
component of the c-secretase complex (presenilin), its substrate
(APP, from amyloid-b precursor protein) and Ab (the small peptide
that results from the processing of APP) are enriched in MAM. On
the other hand, Winkler and collaborators [168], carrying out a sys-
tematic study on the activity of c-secretase reconstituted in mem-
brane model systems differing in the thickness of the lipid bilayer
showed that the generation of the long toxic Ab with 42/43 amino
acids is significantly higher in thinner membranes, probably as a
consequence of changes in presenilin I conformation or tilting.
Therefore, the authors proposed the regulation of the thickness
of c-secretase host membrane as a new potential target for AD
therapy.
Cholesterol also regulates the association between mitochon-
drial and endoplasmic reticulum (ER) membranes in MAM [169],
which means that disturbances in cellular cholesterol content al-
ters the association between the two organelles, predictably with
important consequences for the cell. In fact, a tighter membrane
association (apparently favored by cholesterol depletion [169])
has been found to promote apoptosis resulting from Ca2+ mito-
chondrial overloading.
Another important aspect related to cholesterol regards the role
of caveolin-1, an important component of caveolae, which are
invaginations of the plasma membrane, rich in cholesterol and
with important roles in membrane trafficking and cell signaling
[170]. Caveolin-1, however, is also hosted in MAM and induces
cholesterol efflux from the ER to the plasma membrane, reducing
MAM cholesterol content and its entry into mitochondria [89].
Thus, caveolin-1 deficiency causes free cholesterol accumulation
in mitochondrial membranes, increasing membrane order,
decreasing electron flux through the respiratory chain and increas-
ing ROS generation and apoptotic signaling [89,171], which can be
related to the progression of several diseases. The consequences of
caveolin-1 depletion in cancer were previously described in
Section 2.2.
2.4. Mitochondrial membrane lipid composition changes in aging
The free radical theory of aging [172] stated that normal aging is
the result of the oxidative damage to tissues mediated by free rad-
icals produced as a byproduct of oxidative metabolism. Subse-
quently, mitochondria have been seen as the main source and
target of free radicals in the context of aging [173]. Progressive loss
of mitochondrial function has been associated with aging and sev-
eral experimental evidence have supported this interdependence
[174], including: (i) the occurrence of mitochondrial DNA (mtDNA)
deletions, punctual mutations or depletion; (ii) age-dependent de-
cline in the activity of mitochondrial electron transport complexes;
(iii) increase in the production of oxygen free radicals; (iv) changes
in the morphology of mitochondria and (v) decrease or collapse of
Fig. 3. Aging-promoted changes in mitochondrial membrane lipid composition. Besides morphological and physiological alterations, aging has been reported as holding
consequences in mitochondrial membrane lipid content. A decrease in CL content and alterations in CL remodeling have been proposed to occur with aging, although some
controversy still remains in this subject. An increase in sphingomyelin content and in the cholesterol (Chol) to phospholipid ratio was also suggested, which should be
correlated with the reported increase in membrane order with aging. Overall, membrane alterations can have bioenergetic costs, with a decrease in mitochondrial activity and
ATP production.
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has also been reported in aged cells [175].
The membrane theory for aging conceives life span as being in-
versely related to the content in unsaturated membrane phospho-
lipids [176]. A positive impact of calorie restriction has been
suggested in this context, leading to a decrease in mitochondrial
ROS production in multiple tissues [177] and extending mean
and maximum lifespan in a variety of species [178]. Since lipid per-
oxidation is closely related to ROS-induced toxicity, the benefic ef-
fect of calorie restriction on the aging process is attributed to a
decrease in membrane fatty acid unsaturation, thus diminishing li-
pid peroxidation [179]. Concordantly, calorie restriction has been
reported to decrease the content in PUFAs in membranes from a
number of tissues [180–182].
Changes in mitochondrial membrane fatty acid composition can
also influence oxidative stress by promoting changes in mem-
brane-mediated processes such as proton leakage across the IMM
[183]. Other aging-induced alterations, such as decreased mem-
brane fluidity resulting from lipid peroxidation, as well as de-
creased CL content and altered activity of the respiratory chain
have been reported (Fig. 3). Due to the influence of CL in the activ-
ity of several anionic carrier systems [184–186] and some of the
electron transport complexes [187–191], including their supramo-
lecular arrangements [192,193], alterations in CL content may ac-
count for the reported age-dependent decline in mitochondrial
performance [183]. In fact, this has been supported by data ob-
tained in rat heart [194,195], brain [196] and liver mitochondria
[197], as well as in human epidermal cells [198]. Paradies and
co-workers reported a consistent age-dependent loss of cardiac
mitochondrial CL, correlated with a decreased activity of a number
of proteins including the mitochondrial phosphate transporter
[199], cyt c oxidase [200], adenine nucleotide transporter [200],
carnitine-acylcarnitine translocase [201] and the pyruvate carrier
[202]. It was demonstrated that acetyl-L-carnitine restored the
function of all those CL-dependent proteins by restoring the levels
of CL, although the molecular mechanism underlying this effect
had not been clarified. The authors hypothesized an eventual influ-
ence of acetyl-L-carnitine in the activity of CL synthase [202]. How-
ever, a selective reduction of CL content with aging is still
controversial, since other studies reported no alteration [203] or
even an increase [204] in CL content in rat heart mitochondria,
although in the former the alteration was detected only for inter-
fibrillar mitochondria in Fischer 344 rats. CL remodeling is likelyto be affected during the aging process. Several studies suggest that
CL remodeling may be altered during aging, including an increase
in the content of highly unsaturated fatty acids, namely arachi-
donic and docosahexaenoic acids, and a decrease in linoleic acid
content in aged rat heart mitochondria [205], whereas another
study showed an increase in CL long chain saturated fatty acids
(arachidic and lignoceric acids) [204]. Similar changes were not ob-
served in other phospholipid classes, namely in PE [204–206], or
plasma unesterified fatty acids [205], suggesting the specificity of
the alterations towards CL.
With regard to changes in the amount of othermembrane lipids, a
decrease in total phospholipid with a parallel increase in cholesterol,
resulting in aprogressive aging-dependent increase in themolar ratio
of cholesterol/phospholipid, havebeen reported inhepaticmitochon-
dria fromaged animals [207]. Paradies et al. also reported an increase
in cholesterol (43%) and a decrease in the phospholipid content (15%)
in heart mitochondria, with CL being the principal responsible for
phospholipid loss (28%decrease in aged rats) [195]. Another study re-
ported higher cholesterol content in heart mitochondria, along with
an increased percentage of sphingomyelin [204].
Decreased mitochondrial membrane fluidity, as previously
mentioned, also seems to be a characteristic of aging. Vorbeck
and colleagues [207] reported a significant aging-dependent in-
crease in the lipid structural order as measured by steady-state
fluorescence polarization using the probe 1,6-diphenyl-1,3,5-hexa-
triene, which might be correlated with the increased cholesterol/
phospholipid molar ratio discussed before. A similar effect was re-
ported for brain mitochondria [208].
Altogether, the abovementioned data suggest that the aging
process is associated with a progressive remodeling of mitochon-
drial membranes, which impacts the capacity of mitochondria to
generate ATP and to control apoptotic signaling (Fig. 3). One of
the key players appears to be CL, which has a relevant and critical
role in both aspects. Therefore, it is expectable that strategies able
to delay the loss of CL or avoid CL detrimental alterations should
also delay the loss of mitochondrial capacity and ROS generation,
possibly preventing in this manner some of the cellular phenotypes
associated with aging. An interesting open question in this regard
is whether the possible CL alterations occurring during aging, often
resulting in mitochondrial dysfunction, can be reversed by diet or
exercise. And, in this case, it would be challenging to identify the
mechanisms involved, in order to improve potential strategies to
counteract the aging process.
Fig. 4. Proposed pathways for diet-induced alterations in mitochondrial membrane lipid composition. External factors, such as diet, can create an environmental stress that
impacts the physiologic genetic control (with changes in the expression/genetic regulation of mitochondrial proteins), possibly resulting in an imbalance in the expression of
proteins involved in lipid synthesis or remodeling. The mechanisms involved in the regulation of mitochondrial lipid content through the interaction of external stressors
with genetics/protein expression are currently not known. An alternative mechanism for external dietary interventions to alter mitochondrial membrane lipid composition is
based on a switch in the availability of precursors for lipid synthesis, which can be provided by the diet or further metabolic processing. Another model is based on the
indirect regulation of lipid composition through the modulation of the activity of key-enzymes of lipid metabolism by the membrane lipid environment, which might be
modified (–) by the diet in terms of lipid composition or in terms of biophysical membrane properties. Some proteins that can undergo this type of modulation include TIM
(translocase of the inner mitochondrial membrane), TOM (translocase of the outer mitochondrial membrane), SAM (sorting and assembly machinery), CS (cardiolipin
sinthase), Ups1 and SREBP1 (sterol regulatory element binding protein 1).
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As previously mentioned, mitochondrial lipid composition,
although obeying a characteristic pattern, displays a highly dy-
namic behavior, depending on the physiological or pathological
conditions. This plasticity in lipid composition, sensible to external
modulation may substantiate the emergence of therapeutic appli-
cations. In fact, by modulating the lipid composition of mitochon-
drial membranes and, hence, interfering with mitochondrial
function, it is predictably possible to regulate and improve mito-
chondrial function in the context of injury and disease (Fig. 4). In
this context, the investigation of the mitochondrial alterations in-
duced by diets with different fat composition can be instrumental
to influence cell fate. Studies establishing a correlation between
diet, mitochondria membrane lipid composition and mitochon-
dria/cell physiology will open new trends to identify the etiology
of diseases and to develop novel therapeutic strategies. One possi-
bility is to establish dietary interventions that counteract or pre-
vent alterations of membrane lipid properties associated to the
occurrence of several diseases. In fact, dietary benefits have been
revealed for some diseases, namely cardiovascular. Increasing evi-
dence regarding a correlation between the prevalence of cardiovas-
cular diseases in mammals and the type of lipids included in the
diet has been found [209–211]. Benefits provided by tuna fish
and sunflower seed oils were observed in cases of reduced ventric-
ular fibrillation in occlusion, ventricular tachycardia and risk ofsudden cardiac death [212]. Fish oil also proved to be advanta-
geous against reduced atherogenesis, mortality from coronary
heart disease, intimal hyperplasia and atherosclerosis [213–217].
Preventive effects and cardioprotective properties have also been
reported for rapeseed oil (optimized oils) [218], including reduc-
tion of mortality rate and infarct size [219]. Thus, this oil has been
suggested to be used as a functional supplement, aiding in stroke
prevention and protection. Dietary benefits towards some kinds
of cancer have also been reported, with an inverse correlation be-
tween fish oil consumption and the occurrence of male and female
colorectal cancer [220] and breast carcinoma [220,221]. Advanta-
ges of a dietary control have also been proposed for type 2 diabetes
[222]. Some mitochondrial fatty acid oxidation disorders may be
targeted by dietary intervention, as well [223].
The importance of diet as a valid therapeutic approach is illus-
trated by themanageablemodulation of the acyl chain unsaturation
in CLs. In fact, CL was suggested to be more susceptible to undergo
acyl chain changes upon dietarymanipulation as compared to other
phospholipid classes, such as PC and PE [224]. On the other hand,
some studies revealed that tetraoleoyl-CL did not undergo oxidation
when cyt c/tetraoleoyl-CL complexes were incubated in the pres-
ence of H2O2 [51]. In this context, the enrichment of mitochondrial
membranes with non-oxidizable molecular species of CL was pro-
posed as a potential mechanism for protecting cells against apopto-
sis [51]. Conversely, an increase in PUFAs, resulting in increased
generation of highly oxidizable CL species, wouldmake the targeted
cells more susceptible to oxidative modification and, ultimately, to
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perspective when attempting to develop antitumor strategies to
overcome the increased resistance of tumor cells to pro-apoptotic
drugs [51].
We have also demonstrated recently that rats fed a rapeseed
oil-rich diet for 11, 22 and 33 days undergo alterations of mito-
chondrial membrane lipid composition and properties, as well as
a decrease in state 3 respiration [20]. This study demonstrated that
the modified diet resulted in a higher incorporation of oleic acid in
CL species [20], as well as in a decrease in hydroperoxide produc-
tion by the respiratory chain [20]. One particular learning from
these experiments was that lipid content of mitochondrial mem-
branes was altered after only 11 days of modified, rapeseed oil-
based diet, suggesting that diet can have an immediate effect on
the composition (and properties) of mitochondrial membranes,
modulating the bioenergetics of that organelle.
In another approach, recent data demonstrated that the dietary
content in fatty acids modulated the type of CL species found in the
liver of rats with non-alcoholic fatty liver disease [225]. Interest-
ingly, different dietary fatty acid patterns (lard-rich vs. fish oil-rich
diet) showed to modulate differently CL synthase gene expression
and CL remodeling. Concomitantly, the activity of mitochondrial
proteins was differently affected. While ATP synthase activity
showed a positive correlation with increased CL content, the oppo-
site was observed for complex II + III activity [225]. The differential
effects of dietary fatty acid patterns on CL species impact mito-
chondrial capacity, which, in its turn, may interfere with beta-oxi-
dation of fatty acids, thus resulting in progression of the disease.
Taking all previous data into account, it seems fair to emphasize
the relevance that dietary approaches may hold in a therapeutic
context. The synergistic effects of diet and pharmacological drugs,
namely mitochondria-active compounds, could also represent a
valid path to explore.
Some evidence have been accumulated underlining the influ-
ence of dietary lipids in the action of certain membrane-active
drugs (e.g., anesthetics and alcohols) [226]. A correlation between
diet-induced changes in membrane lipid composition and the
pharmacological effects of volatile anesthetics, such as halothane,
isoflurane, methoxyflurane and cyclopropane, has been established
[227]. The authors demonstrated that the increased anesthetic ac-
tion in rats fed a fat-free diet was specifically reversed by linoleic
acid supplementation. The action of the local anesthetic tetracaine
was also proposed to be dependent on lipid membrane composi-
tion [228]. Curcumin, a natural spice used for generations in tradi-
tional medicines, was proposed to indirectly regulate the action of
membrane proteins by changing the physical properties of the
membrane rather than acting by direct binding to proteins [229].
Similarly, many other molecules, including drugs and environmen-
tal contaminants, particularly those whose lipophilicity implies a
strong incorporation into the lipid bilayer, have shown a biological
activity mediated or highly influenced by direct interactions with
membrane lipids [230–239]. Therefore, it is fair to assume that bio-
logical effects of such compounds should be modulated by an
appropriate diet.
Focusing specifically on mitochondria, it was reported that the
ATPase of heart mitochondria from animals fed diets with an high
content in long chain-fatty acids exhibited increased oligomycin
sensitivity and decreased 2,4-dinitrophenol-induced stimulation
[240]. The authors suggested that in vivo changes in the thickness
of the lipid bilayer might alter mitochondrial ATPase activity.
Studies carried out in our laboratory with a great diversity of
compounds, including drugs [233,234], insecticides [241], herbi-
cides [242] and other synthetic compounds [243,244], which exhi-
bit high toxicity towards mitochondrial functioning, have
suggested that mitochondriotoxicity is often mediated by effects
exerted by the compounds on mitochondrial membrane lipids.Thus, data gathered from biophysical studies using different tech-
nical approaches and a variety of membrane model systems
showed that membrane physical properties, such as fluidity, lateral
heterogeneity and curvature stress, were affected by those com-
pounds in such a manner that adverse repercussions would be ex-
pected in mitochondrial functioning [233,234,237,243–247].4. Open perspectives and words of caution
Therapies addressed to mitochondrial lipids may be success-
fully used in the context of mitochondrial disease and dysfunction,
due to the strict association of lipids such as CL with mitochondria
membrane proteins and their involvement in mitochondrial func-
tion. Recent evidence suggests membrane-lipid therapies as poten-
tially useful by themselves or in combination with other therapies,
to treat common pathologies, such as cancer, cardiovascular dis-
eases, neurodegenerative processes, obesity, metabolic disorders,
inflammation, and infectious and autoimmune diseases, but only
future studies will enable determining the full potential of this no-
vel therapeutic approach [248]. Most drugs used with pharmaco-
logical purposes have been designed to target specific membrane
proteins, at relatively low concentrations. However, some of these
drugs hold side pharmacological effects at higher concentrations
[249]. These less specific effects towards membrane-associated
proteins may arise from the interaction of lipophilic drugs with
the lipid bilayer, causing changes in their structural and elastic
properties, and resulting in alterations of protein distribution in
the plane of the membrane and/or in alterations of protein func-
tional conformation [249–252]. The intricate interplay between
lipids and membrane protein structure and function makes it rea-
sonable to infer that lipid bilayers may influence drug action to-
wards membrane protein targets also at low concentrations. The
disruption of membrane lipid rafts and alterations of protein distri-
bution between raft and non-raft domains have been proposed as
the means by which drugs may influence membrane protein activ-
ity with a relative specificity [253].
Considering all datamentioned above, the use of specific diets to
modulate drug membrane-activity should seriously be taken into
account in situations of eithermanagingmembrane-localized toxic-
ity or potentiating treatment in a disease context. Dietmanipulation
may then represent a way to reduce the toxic outcomes brought by
the use of some drugs or to assist their pharmacological action. Fur-
ther work is necessary in order to fully appraise the potential of die-
tary interventions in improving the chemotherapeutic activity of
pharmacological agents. In this context, membrane lipid-mediated
therapeutic strategies have been proposed [248], in which the
molecular targets are the lipids and the structures they form (mem-
brane-lipid therapy). The final goal of this approach is to develop
drugs able to control the activity of membrane-associated proteins
by regulating membrane lipid composition and/or structure.
Finally, it is clear that CL has a very special role in the modula-
tion of mitochondrial function at health and disease conditions,
determining also the triggering of the mitochondrial pathway for
apoptosis. Since it has been demonstrated that CL synthase has
the unexpected role of modulating the physiology of mitochondrial
membranes, increasing their resistance to metabolic stress [142],
one can aim at targeting this enzyme to improve a mitochondrial
disease-related phenotype. How this can be achieved or which
pathologies can be targeted by this approach are questions that re-
quire further investigation. Finally, a word of caution: despite
many mechanisms have been proposed implicating CL content
alterations in different pathologies, this may also result from vari-
ations in the overall mitochondrial mass. This is often an over-
looked aspect in many studies, in which proper internal standards
(e.g., CL content/citrate synthase activity) should be used.
524 J.P. Monteiro et al. / Progress in Lipid Research 52 (2013) 513–528Nevertheless, there is strong and clear evidence that in Barth syn-
drome, among other conditions, disruption of CL metabolism re-
sults in a decrease of CL mass without loss of mitochondrial
content [254,110]. Other works, however, overlooked the determi-
nation of CL content/mitochondrial units [136,255]. Therefore, cau-
tion should be taken prior to infer that different conditions result
in a decrease in CL content without ensuring that mitochondrial
copy number in cells remained constant.
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